Risk of Non-melanoma Skin Cancer with Biological Therapy in Common Inflammatory Diseases: a Systemic Review and Meta-analysis

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 Nov 23

PMID 34809619

Citations 8

Authors

Ruolin Liu

Qianyi Wan

Rui Zhao

Haitao Xiao

Ying Cen

Xuewen Xu

Affiliations

Soon will be listed here.

Abstract

Background: Most previous studies compared the risk for non-melanoma skin cancer (NMSC) in biologic-treated common inflammatory diseases with the general population. Whether the increased NMSC risk is caused by the disease itself, the biologics, or both remains unknown.

Methods: We systematically searched PubMed, Embase, Medline, Web of Science, and Cochrane Library from inception to May 2021. Studies were included if they assessed the risk of NMSC for rheumatoid arthritis (RA), inflammatory bowel disease (IBD), or psoriasis patients treated with biologics compared with patients not receiving biologics. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using the fixed- or random-effects model.

Results: The current meta-analysis included 12 studies. Compared with patients with the inflammatory disease without biologics, patients receiving biological therapy were associated with an increased risk for NMSC (RR 1.25, 95% CI 1.14 to 1.37), especially in patients with RA (RR 1.24, 95% CI 1.13 to 1.36) and psoriasis (RR 1.28, 95% CI 1.07 to 1.52), but not in patients with IBD (RR 1.49, 95% CI 0.46 to 4.91). The risks for squamous cell skin cancer and basal cell skin cancer were both increased for patients receiving biologics. However, the risk of NMSC did not increase in patients treated with biologics less than 2 years.

Conclusions: Current evidence suggests that increased risk of NMSC was identified in RA and psoriasis treated with biologics compared with patients not receiving biologics, but not in patients with IBD. The inner cause for the increased risk of NMSC in IBD patients should be further discussed.

Citing Articles

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review.

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W Postepy Dermatol Alergol. 2025; 41(6):552-559.

PMID: 39877117 PMC: 11770571. DOI: 10.5114/ada.2024.143428.

Gene-Environment Interaction: Small Deletions (DELs) and Transcriptomic Profiles in Non-Melanoma Skin Cancer (NMSC) and Potential Implications for Therapy.

Jasmine F, Almazan A, Khamkevych Y, Argos M, Shahriar M, Islam T Cells. 2025; 14(2.

PMID: 39851523 PMC: 11764317. DOI: 10.3390/cells14020095.

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.

Rubbert-Roth A, Kato K, Haraoui B, Rischmueller M, Liu Y, Khan N Rheumatol Ther. 2024; 11(5):1197-1215.

PMID: 39031276 PMC: 11422392. DOI: 10.1007/s40744-024-00694-x.

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.

Fleischmann R, Swierkot J, Penn S, Durez P, Bessette L, Bu X RMD Open. 2024; 10(2).

PMID: 38806190 PMC: 11138271. DOI: 10.1136/rmdopen-2023-004007.

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Burmester G, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo V, Coombs D Rheumatol Ther. 2024; 11(3):737-753.

PMID: 38683479 PMC: 11111431. DOI: 10.1007/s40744-024-00671-4.

References

Kamm M . Rapid changes in epidemiology of inflammatory bowel disease. Lancet. 2017; 390(10114):2741-2742. DOI: 10.1016/S0140-6736(17)32669-7. View

Haynes K, Beukelman T, Curtis J, Newcomb C, Herrinton L, Graham D . Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2012; 65(1):48-58. PMC: 3778442. DOI: 10.1002/art.37740. View

Ruiz de Morales J, Puig L, Dauden E, Canete J, Pablos J, Olveira Martin A . Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2019; 19(1):102429. DOI: 10.1016/j.autrev.2019.102429. View

Ishiyama K, Suwa A, Goto M, Hirakata M, Inoue K, Hara M . Malignant melanoma in a patient with rheumatoid arthritis. Clin Exp Rheumatol. 1998; 16(4):507. View

Chatzikyriakidou A, Georgiou I, Voulgari P, Drosos A . The role of tumor necrosis factor (TNF)-alpha and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. Clin Exp Rheumatol. 2009; 27(4):645-8. View

Muller M, DAmico F, Bonovas S, Danese S, Peyrin-Biroulet L . TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2020; 15(5):840-859. DOI: 10.1093/ecco-jcc/jjaa186. View

Esse S, Mason K, Green A, Warren R . Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020; 156(7):787-794. PMC: 7240639. DOI: 10.1001/jamadermatol.2020.1300. View

Asgari M, Ray G, Geier J, Quesenberry C . Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017; 76(4):632-638. DOI: 10.1016/j.jaad.2016.10.006. View

Wolfe F, Michaud K . Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007; 56(9):2886-95. DOI: 10.1002/art.22864. View

10.

Long M, Martin C, Pipkin C, Herfarth H, Sandler R, Kappelman M . Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012; 143(2):390-399.e1. PMC: 4065572. DOI: 10.1053/j.gastro.2012.05.004. View

11.

Parisi R, Iskandar I, Kontopantelis E, Augustin M, Griffiths C, Ashcroft D . National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020; 369:m1590. PMC: 7254147. DOI: 10.1136/bmj.m1590. View

12.

Singh A, Fatima K, Singh A, Behl A, Mintoo M, Hasanain M . Anticancer activity and toxicity profiles of 2-benzylidene indanone lead molecule. Eur J Pharm Sci. 2015; 76:57-67. DOI: 10.1016/j.ejps.2015.04.020. View

13.

Nebbia M, Yassin N, Spinelli A . Colorectal Cancer in Inflammatory Bowel Disease. Clin Colon Rectal Surg. 2020; 33(5):305-317. PMC: 7500966. DOI: 10.1055/s-0040-1713748. View

14.

Narazaki M, Tanaka T, Kishimoto T . The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 2017; 13(6):535-551. DOI: 10.1080/1744666X.2017.1295850. View

15.

Chiu Y, Chen D . Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2019; 16(2):207-228. DOI: 10.1080/1744666X.2019.1705785. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

17.

Soderlund S, Brandt L, Lapidus A, Karlen P, Brostrom O, Lofberg R . Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009; 136(5):1561-7. DOI: 10.1053/j.gastro.2009.01.064. View

18.

Calip G, Patel P, Adimadhyam S, Xing S, Wu Z, Sweiss K . Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018; 143(5):1062-1071. PMC: 6103834. DOI: 10.1002/ijc.31407. View

19.

Solomon D, Kremer J, Fisher M, Curtis J, Furer V, Harrold L . Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2013; 43(4):489-97. DOI: 10.1016/j.semarthrit.2013.08.003. View

20.

Singh S, Nagpal S, Murad M, Yadav S, Kane S, Pardi D . Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 12(2):210-8. DOI: 10.1016/j.cgh.2013.04.033. View